RESUMO
The factor H (FH) protein (also known as beta1H globulin) is the main regulator of the complement alternative pathway. It exhibits multivalent binding sites to the complement component C3b, and polyanions and one binding site to sialic acid and cell surfaces. These multiple binding sites confer to FH a decay-accelerating factor activity in the fluid phase as well as at the cell surface. A defect in FH activity or a FH protein deficiency triggers chronic inflammation and tissue injury, leading to various disorders impacting the kidney or the eye. In contrast, some pathogens, as well as cancer cells, develop various strategies to bind FH and thereby subvert a complement attack. We focus on the functions of FH, and review the main pathological conditions in which FH is involved. Since the pathogenesis is elusive, appropriate FH dosage in biological fluids and FH gene analysis may help in improving understanding of such diseases.
Assuntos
Fator H do Complemento/fisiologia , Animais , Artrite Reumatoide/imunologia , Ativação do Complemento , Fator H do Complemento/análise , Fator H do Complemento/genética , Humanos , Infecções/imunologia , Inflamação/imunologia , Nefropatias/imunologia , Neoplasias/imunologiaRESUMO
Landfill bioreactors are based on an acceleration of in-situ waste biodegradation by performing leachate recirculation. To quantify the water content and to evaluate the leachate injection system, in-situ methods are required to obtain spatially distributed information, usually electrical resistivity tomography (ERT). In a previous study, the MICS (multiple inversions and clustering strategy) methodology was proposed to improve the hydrodynamic interpretation of ERT results by a precise delimitation of the infiltration area. In this study, MICS was applied on two ERT time-lapse data sets recorded on different waste deposit cells in order to compare the hydrodynamic behaviour of leachate flow between the two cells. This comparison is based on an analysis of: (i) the volume of wetted waste assessed by MICS and the wetting rate, (ii) the infiltration shapes and (iii) the pore volume used by the leachate flow. This paper shows that leachate hydrodynamic behaviour is comparable from one waste deposit cell to another with: (i) a high leachate infiltration speed at the beginning of the infiltration, which decreases with time, (ii) a horizontal anisotropy of the leachate infiltration shape and (iii) a very small fraction of the pore volume used by the leachate flow. This hydrodynamic information derived from MICS results can be useful for subsurface flow modelling used to predict leachate flow at the landfill scale.
Assuntos
Modelos Teóricos , Eliminação de Resíduos/métodos , Resíduos Sólidos/análise , Instalações de Eliminação de Resíduos , Poluentes Químicos da Água/análise , Biodegradação Ambiental , Reatores Biológicos , Hidrodinâmica , Movimentos da ÁguaRESUMO
Performances of cationic lipid formulations for intravenous gene delivery to mouse lungs have been previously reported. We report in this study that cationic phosphonolipids, when appropriately formulated, can be good synthetic vectors for gene delivery to lung after intravenous administration. One of our reagents, GLB43, was capable of mediating a 500-fold higher expression in the lungs of mice than could be obtained with free pDNA alone (P=0.018). We demonstrate that the most important parameters for cationic phosphonolipid transfection activity after systemic administration are the chemical structure of the cationic phosphonolipid, the lipid to DNA charge ratio and the inclusion of co-lipid in the formulation. We report using a luciferase reporter gene that transfection activity in vivo 24 h after cationic phosphonolipid systemic administration could not be predicted from in vitro analysis. In contrast to in vitro studies, cationic phosphonolipids including the oleyl acyl chains (GLB43) were more effective than its analogue with the myristyl acyl chains (GLB73). Using pathological analysis of animal livers, we demonstrate that the toxicity level was correlated with the lipoplex formulation and the lipid to DNA ratio.
Assuntos
DNA/toxicidade , Pulmão/metabolismo , Fosfolipídeos/toxicidade , Animais , Linhagem Celular , Colesterol/química , DNA/química , Desenho de Fármacos , Genes Reporter , Terapia Genética , Injeções Intravenosas , Fígado/efeitos dos fármacos , Fígado/patologia , Luciferases/análise , Camundongos , Fosfatidiletanolaminas/química , Fosfolipídeos/química , Fosfolipídeos/genética , Plasmídeos , Transfecção/métodosRESUMO
Hypoxic niches help maintain mesenchymal stromal cell properties, and their amplification under hypoxia sustains their immature state. However, how MSCs maintain their genomic integrity in this context remains elusive, since hypoxia may prevent proper DNA repair by downregulating expression of BRCA1 and RAD51. Here, we find that the ING1b tumor suppressor accumulates in adipose-derived stromal cells (ADSCs) upon genotoxic stress, owing to SUMOylation on K193 that is mediated by the E3 small ubiquitin-like modifier (SUMO) ligase protein inhibitor of activated STAT protein γ (PIAS4). We demonstrate that ING1b finely regulates the hypoxic response by triggering HIF1α proteasomal degradation. On the contrary, when mutated on its SUMOylation site, ING1b failed to efficiently decrease HIF1α levels. Consistently, we observed that the adipocyte differentiation, generally described to be downregulated by hypoxia, was highly dependent on ING1b expression, during the early days of this process. Accordingly, contrary to what was observed with HIF1α, the absence of ING1b impeded the adipogenic induction under hypoxic conditions. These data indicate that ING1b contributes to adipogenic induction in adipose-derived stromal cells, and thus hinders the phenotype maintenance of ADSCs.
Assuntos
Tecido Adiposo/citologia , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Peptídeos e Proteínas de Sinalização Intracelular/metabolismo , Proteínas Nucleares/metabolismo , Sumoilação , Proteínas Supressoras de Tumor/metabolismo , Hipóxia Celular , Linhagem da Célula , Células Cultivadas , Dano ao DNA , Inativação Gênica , Humanos , Proteína 1 Inibidora do Crescimento , Modelos Biológicos , Proteínas de Ligação a Poli-ADP-Ribose , Proteínas Inibidoras de STAT Ativados/metabolismo , Estabilidade Proteica , Proteólise , Células Estromais/metabolismoRESUMO
Several studies have demonstrated that intravenous administration of DNA complexed with cationic lipid vectors induces the production of large quantities of proinflammatory cytokines. In this study we confirm these observations, using cationic lipid DOTAP and cationic phospholipid compounds. Moreover, we demonstrate that although intravenous administration of lipid-DNA complexes does not induce toxic effects in the lung, high transgene expression in lung correlates with histopathological lesions in liver, this fact being documented by high transaminase levels in serum of treated mice. We examine the contribution of various components of the lipoplexes in this observed liver toxicity, as well as in the increasing level of transaminases, and more particularly the role of nonmethylated CpG sequences of plasmid DNA. We show that blood samples from animals treated either with cationic lipid alone, or with cationic lipid complexed with methylated plasmid DNA, contain low levels of transaminases. The significant decrease in transaminase levels after injection of cationic lipid-methylated pDNA complexes leads us to believe that nonmethylated CpG sequences could play a major role in this hepatoxicity. Similar results were observed when using a vector that did not encode a transgene, demonstrating that the expression of luciferase in lung was not responsible for this liver toxicity. All these observations suggest that significant work should be devoted to understand more clearly the mechanism of cationic lipid-DNA complex toxicity, and to overcome the problems subsequent to administration of non-methylated CpG sequences of plasmid DNA.
Assuntos
Ilhas de CpG/imunologia , Técnicas de Transferência de Genes , Fígado/efeitos dos fármacos , Plasmídeos/genética , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Animais , Aspartato Aminotransferases/sangue , Cátions , Células Cultivadas , Metilação de DNA , Portadores de Fármacos , Ácidos Graxos Monoinsaturados/química , Feminino , Corantes Fluorescentes/química , Injeções Intravenosas , Lipídeos , Lipossomos , Fígado/patologia , Luciferases/genética , Pulmão/metabolismo , Camundongos , Camundongos Endogâmicos , Compostos de Amônio Quaternário/química , TransfecçãoRESUMO
Cationic lipids have been shown to be an interesting alternative to viral vector-mediated gene delivery into in vitro and in vivo model applications. Prior studies have demonstrated that even minor structural modifications of the lipid hydrophobic domain or of the lipid polar domain result in significant changes in gene delivery efficiency. Previously, we developed a novel class of cationic lipids called cationic phosphonolipids and described the ability of these vectors to transfer DNA into different cell lines and in vivo. Up until now, in all new cationic lipids, nitrogen atoms have always carried the cationic or polycationic charge. Recently we have developed a new series of cationic phosphonolipids characterized by a cationic charge carried by a phosphorus or arsenic atom. In a second step, we have also examined the effects of the linker length between the cation and the hydrophobic domain as regards transfection activity. Transfection activities of this library of new cationic phosphonolipids were studied in vitro in different cell lines (HeLa, CFT1, K562) and in vivo using a luciferase reporter gene. A luminescent assay was carried out to assess luciferase expression. We demonstrated that cation substitution on the polar domain of cationic phosphonolipids (N --> P or As) results in significant increase in transfection activity for both in vitro and in vivo assays and decrease of cellular toxicity.
Assuntos
Técnicas de Transferência de Genes , Fosfolipídeos/síntese química , Alanina Transaminase/sangue , Animais , Aspartato Aminotransferases/sangue , Cátions , Linhagem Celular , Feminino , Genes Reporter , Vetores Genéticos , Humanos , Luciferases/genética , Luciferases/metabolismo , Medições Luminescentes , Camundongos , Fosfolipídeos/química , Fosfolipídeos/toxicidade , Relação Estrutura-Atividade , TransfecçãoRESUMO
Since the development of the concept of gene therapy using cationic lipids as nonviral vectors by Felgner's group in 1987, numerous molecules have been synthesized. Such vectors were first proposed to avoid viral vector-induced drawbacks. But, it quickly became clear that a thorough knowledge of their physical and chemical characteristics was fundamental to use them under optima conditions. Over the last years our laboratory has developed a family of cationic lipids called phosphonolipids whose structure is based on that of natural phosphonolipids; compared with other vectors, these compounds had to be well-tolerated by biologic membranes. Some of our synthesized molecules exhibited an interesting potential for gene transfer, both in vitro and in vivo. Structural changes in the different parts (hydrophobic, hydrophilic, and intermediary domains) of these vectors were evaluated in vitro on different cell-lines; these studies led us to select some of these molecules to carry out in vivo tests. So, the plasmid/phosphonolipid complexes were first administered to mice by intratracheal and aerosol routes with a beta-galactosidase plasmid as reporter gene. In a second set of experiments, we explored the possibilities offered by intravenous injection; in these studies, we used a luciferase plasmid as reporter gene because of its high sensibility. These experiments revealed a transgene expression essentially localized in the lungs. In a further study, we compared systemic administration with local ones; we, then, observed that the optimum formulation of a given molecule depended on its route of administration.
Assuntos
Vetores Genéticos , Fosfolipídeos , Aerossóis , Animais , Cátions , Linhagem Celular , Células Cultivadas , Vias de Administração de Medicamentos , Genes Reporter , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , Vetores Genéticos/química , Humanos , Injeções Intravenosas , Células K562 , Camundongos , Fosfolipídeos/administração & dosagem , Fosfolipídeos/químicaRESUMO
The objectives of this study were to test the influence of different parameters on the in vivo cationic lipid mediated gene transfer in lung after intravenous administration. Luciferase activity was evaluated in lung tissue 24 hours after intravenous administration of different types of lipoplexes. These included lipoplexes prepared using cationic phosphonolipids or DOTAP and various amounts of plasmid DNA. Using two different plasmids we tested the influence of plasmid size on transfection efficiency in vivo. In a last series of experiments, lipoplexes were prepared using different excipients (water, NaCl or 5% glucose solution) and three injection volumes were tested. We demonstrate that chemical structure modifications such as cation substitution and increment of the aliphatic chain length significantly improve transfection efficiency. High luciferase levels are obtained by increasing lipid to DNA charge ratio and plasmid DNA dose and decreasing plasmid size. Lipoplexes prepared in physiological NaCl solution and injected using a volume of 800mul are significantly the most effective. Cationic lipid mediated gene transfer in lung tissue after intravenous administration is influenced by factors including cationic lipid chemical structure, lipid to DNA ratio and plasmid dose. Nevertheless, plasmid size, injection volume and the excipient, used for the lipoplexes preparation, are also important factors and must be considered for an optimization of in vivo gene delivery using intravenous administration.
RESUMO
Replacing the ammonium polar head in cationic lipids 1 (A=N) by a phosphonium or an arsonium group (A=P, As) improves their properties as synthetic vectors for DNA transfection. The increased volume of the cationic head is supposed to modify the interactions of the vector with the solvent and DNA.
RESUMO
With the aim of developing new efficient agents for transfecting of eukaryotic cells we have designed and synthesized a novel family of cationic lipid vectors derived from glycine betaine. In this study we present three novel molecules differing by the length of their aliphatic chains (R=12,R=14,R=16). The lyotropic properties of these cationic lipids have been determined, and their transfection efficiency on different cell lines evaluated, using a luminescent assay. Two of these compounds, GB14 and GB12 are efficient in vitro experiments. Cytoxicity evaluation of these new molecules showed promising results with a low cytotoxicity, especially when co-lipids were included in the formulation. These compounds represent a new family of gene transfer vectors which display good transfection efficiency and low toxicity, possibly due to the natural properties of glycine betaine. These compounds have great potential for the future development of in vivo gene transfer protocols.
Assuntos
Betaína/análogos & derivados , Materiais Biocompatíveis/metabolismo , Técnicas de Transferência de Genes , Betaína/síntese química , Betaína/toxicidade , Materiais Biocompatíveis/síntese química , Materiais Biocompatíveis/toxicidade , Cátions/toxicidade , Células HT29 , Humanos , Células K562 , Lipossomos/genética , Fosfatidiletanolaminas/genética , Soluções , Testes de Toxicidade , TransfecçãoRESUMO
Glioblastoma multiforme (GBM) remains the most devastating primary tumour in neuro-oncology. Targeting of the human epithelial receptor type 2 (HER2)-neu receptor by specific antibodies is a recent well-established therapy for breast tumours. Human epithelial receptor type 2/neu is a transmembrane tyrosine/kinase receptor that appears to be important for the regulation of cancer growth. Human epithelial receptor type 2/neu is not expressed in the adult central nervous system, but its expression increases with the degree of astrocytoma anaplasia. The specificity of HER2/neu for tumoral astrocytomas leads us to study in vitro treatment of GBM with anti-HER2/neu antibody. We used human GBM cell lines expressing HER2/neu (A172 express HER2/neu more than U251MG) or not (U87MG) and monoclonal humanised antibody against HER2/neu (Herceptin). Human epithelial receptor type 2/neu expression was measured by immunohistochemistry and flow cytometry. Direct antibody effect, complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity were evaluated by different cytometric assays. We have shown, for the first time, the ability of anti-HER2/neu antibodies to induce apoptosis and cellular-dependent cytotoxicity of HER2/neu-expressing GBM cell lines. The results decreased from A172 to U251 and were negative for U87MG, in accordance with the decreasing density of HER2/neu receptors.